Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022
July 28 2022 - 4:15PM
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a
clinical-stage biopharmaceutical company focused on improving
the intracellular delivery of nucleic acids and small molecules
with its lipid nanocrystal (LNC) platform technology, today
announced the Company will host a conference call and live audio
webcast on Thursday, August 11, 2022 at 8:30 a.m. ET to discuss
operational and financial results for the second quarter ended June
30, 2022.
To participate in the call, please dial (877)
407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference
conference ID 13730276. The live webcast will be accessible on the
Investors section of Matinas’ website,
www.matinasbiopharma.com, and archived for 90 days.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company
focused on improving the intracellular delivery of nucleic acids
and small molecules with its lipid nanocrystal (LNC) platform
technology. The Company is developing its own internal portfolio of
products as well as partnering with leading pharmaceutical
companies to develop novel formulations that capitalize on the
unique characteristics of the LNC platform.
Preclinical and clinical data have demonstrated
that this novel technology can provide solutions to many of the
challenges in achieving safe and effective intracellular delivery,
for both small molecules and larger, more complex molecules, such
as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines.
The combination of a unique mechanism of action and flexibility
with formulation and route of administration (including oral),
positions Matinas’ LNC technology to potentially become the
preferred next-generation intracellular drug delivery vehicle with
distinct advantages over both lipid nanoparticles and viral
vectors.
The Company is focused on developing an internal
and external pipeline of drugs candidates based on the LNC
platform. Internally, the Company has two clinical stage assets.
MAT2203 is an oral, LNC formulation of the highly potent antifungal
medicine amphotericin B, currently for a Phase 3 registration
trial; MAT2501 is an oral, LNC formulation of the broad-spectrum
aminoglycoside, amikacin, primarily used to treat chronic and acute
bacterial infections, and currently in Phase 1. Externally, the
Company has established a broad set of relationships with multiple
global pharmaceutical collaborators, including BioNTech (mRNA), the
National Institutes of Health and Gilead Sciences (antivirals), and
Genentech, a member of the Roche Group (small molecules, antisense
oligonucleotides, and antibody fragments).
For more information, please visit
www.matinasbiopharma.com.
Forward Looking Statements:
This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to our business
activities, our strategy and plans, the potential of our LNC
platform delivery technology, and the future development of its
product candidates, including MAT2203, MAT2501, the anticipated
timing of regulatory submissions, the anticipated timing of
clinical studies, the anticipated timing of regulatory
interactions, the Company’s ability to identify and pursue
development and partnership opportunities for its products or
platform delivery technology on favorable terms, if at all, and the
ability to obtain required regulatory approval and other statements
that are predictive in nature, that depend upon or refer to future
events or conditions. All statements other than statements of
historical fact are statements that could be forward-looking
statements. Forward-looking statements include words such as
"expects," "anticipates," "intends," "plans," "could," "believes,"
"estimates" and similar expressions. These statements involve known
and unknown risks, uncertainties and other factors which may cause
actual results to be materially different from any future results
expressed or implied by the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our ability to obtain
additional capital to meet our liquidity needs on acceptable terms,
or at all, including the additional capital which will be necessary
to complete the clinical trials of our product candidates; our
ability to successfully complete research and further development
and commercialization of our product candidates; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to protect the
Company’s intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company’s products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma’s product candidates are all in a
development stage and are not available for sale or use.
Investor and Media Contact
Peter VozzoICR
Westwicke443-213-0505peter.vozzo@westwicke.com
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Apr 2023 to Apr 2024